1. Home
  2. VUZI vs EDIT Comparison

VUZI vs EDIT Comparison

Compare VUZI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vuzix Corporation

VUZI

Vuzix Corporation

HOLD

Current Price

$3.51

Market Cap

246.0M

Sector

Technology

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.14

Market Cap

213.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VUZI
EDIT
Founded
1997
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
246.0M
213.8M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
VUZI
EDIT
Price
$3.51
$2.14
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.50
AVG Volume (30 Days)
3.1M
1.8M
Earning Date
11-13-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,310,001.00
$46,383,000.00
Revenue This Year
$5.53
N/A
Revenue Next Year
$110.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.47
$0.91
52 Week High
$5.79
$4.54

Technical Indicators

Market Signals
Indicator
VUZI
EDIT
Relative Strength Index (RSI) 57.33 39.94
Support Level $3.15 $1.95
Resistance Level $4.04 $2.61
Average True Range (ATR) 0.35 0.13
MACD 0.05 -0.01
Stochastic Oscillator 63.87 28.03

Price Performance

Historical Comparison
VUZI
EDIT

About VUZI Vuzix Corporation

Vuzix Corp is engaged in the design, manufacture, and marketing of Artificial Intelligence (AI)-powered Smart Glasses, Waveguides, and Augmented Reality (AR) technologies. Its solutions serve the enterprise, medical, defense, security, and select consumer markets, offering cutting-edge wearable computing and display technologies that enhance productivity and operational efficiency. Its products include near-eye displays (NEDs), heads-up displays (HUDs), and wearable computing devices. Geographically, the company generates a majority of its revenue from the United States and also has a presence in Japan, the Netherlands, and other countries.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: